Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron

Shots:The P-III (ACHIEVE-1) trial assessed orforglipron vs PBO in T2D adults (n=559) having inadequate glycemic control with diet & exercise alone; subjects started at 1mg QD, with dose escalation at every Q4W till assigned doses of 3, 12mg (via 1, 3 & 6mg), or 36mg (via 1, 3, 6, 12, & 24mg)Trial met…

ByPrince GiriApril 18, 2025

News

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots:Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseasesAs per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2025

Shots:  Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata PharmaShots brings…

ByRidhi RastogiApril 1, 2025

News

Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases

Shots:The P-II (ALPACA) trial assessed lepodisiran (16, 96, or 400mg) vs PBO for ~18mos. in 320 pts, who were dosed at baseline & day 180, with an additional arm receiving 400mg at baseline & PBO at day 180; P-III [ACCLAIM-Lp(a)] trial enrollment is ongoingTrial met its 1EP, with 400mg reducing Lp(a) by 93.9%…

ByRidhi RastogiMarch 31, 2025

TOP 20

Top 20 Radiopharmaceutical Companies of 2025

Shots:Imaging, precision diagnostics, and targeted therapies are among the many ways radiopharmaceuticals improve patient outcomes and meet unmet healthcare needsIn 2024, the global radiopharmaceuticals market was valued at $6.74B and is envisioned to grow to $13.67B by 2033, exhibiting a CAGR of 8.2% from 2024 to 2033. Lilly ranks first in our list…

ByPrince GiriMarch 27, 2025

News

Eli Lilly and Incyte Highlight P-III (BRAVE-AA-PEDS) Trial Data of Baricitinib for Alopecia Areata at AAD 2025

Shots:The P-III (BRAVE-AA-PEDS) trial assessed baricitinib (2 or 4mg, QD, PO) vs PBO in 257 pts (12 to <18yrs.) with severe AA, where 89% had significant scalp hair loss, 65% had minimal/no eyebrow hair, & 57% had minimal/no eyelash hair with ClinRO of 2/3; next cohort (6 to <12yrs) enrollment to start in 2026…

ByRidhi RastogiMarch 11, 2025

News

Magnet Biomedicine Partners with Eli Lilly to Advance Molecular Glue Therapeutics in Oncology

Shots:Magnet Biomedicine & Eli Lilly have entered into a collaboration & license agreement to identify, develop & commercialize molecular glue therapeutics in oncology using Magnet's TrueGlue discovery platform As per the deal, Magnet will get ~$40M in upfront, near-term payments & equity, plus more than $1.25B in milestones across development, regulatory, & commercial…

ByRidhi RastogiMarch 3, 2025

News

Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis

Shots:OliX & Eli Lilly have entered into a global license agreement to develop & commercialize OliX’s OLX75016 for metabolic-associated steatohepatitis (MASH) as well as other cardiometabolic indications As per the agreement, Eli Lilly will make an initial payment of ~$630M to OliX for completing the ongoing P-I trial of OLX75016 in Australia, after…

ByRidhi RastogiFebruary 11, 2025

News

Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn’s Disease

Shots:Eli Lilly has reported 2yrs. data from VIVID-2 (OLE) study (incl. 1yr. of VIVID-1) of Omvoh for mod. to sev. Crohn's disease; regulatory review is underway in China, Canada, Japan & other regions In VIVID-1, 92.9% pts sustained clinical remission (CDAI) and 78.6% retained endoscopic remission (SES-CD ≤4 & ≥2-point decrease, with no…

ByRidhi RastogiFebruary 10, 2025

News

Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn’s Disease (CD)

Shots:Approval was based on a P-III (VIVID-1) trial assessing Omvoh vs PBO in mod. to sev. CD patients, unresponsive/intolerable to corticosteroids, BRMs &/or biologics, post its approval for UC in Dec 2023. Regulatory submissions are filed globally, incl. Japan & the EU, with other submissions underway Study showed 53% vs 36% clinical remission &…

ByRidhi RastogiJanuary 16, 2025

Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

PharmaShots’ Key Highlights of First Quarter 2025

Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases

Top 20 Radiopharmaceutical Companies of 2025

Eli Lilly and Incyte Highlight P-III (BRAVE-AA-PEDS) Trial Data of Baricitinib for Alopecia Areata at AAD 2025

Magnet Biomedicine Partners with Eli Lilly to Advance Molecular Glue Therapeutics in Oncology

Eli Lilly Acquires OLX75016 from OliX Pharmaceuticals for Metabolic-Associated Steatohepatitis

Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn’s Disease

Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn’s Disease (CD)

Contact US

OUR INFORMATION

FOLLOW US